Clarity Pharmaceuticals Ltd (ASX: CU6) - ETF Exposure

- Current share price for CU6 : $1.825

Clarity Pharmaceuticals Ltd (CU6) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It operates as a clinical stage radiopharmaceutical entity focused on treatment of serious diseases. The organisation develops TCTs based on the SAR Technology Platform for treatment of cancers.

CU6 General Information ⁺

ASX Code	CU6
Website	http://www.claritypharmaceuticals.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	680
CU6 Share Price	$1.825
Day High	$1.855
Day Low	$1.778
Last Close	$1.825
CU6 Share Price Movement	- ( No change )

Prices as at 16:40, 14 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CU6

Clarity Pharmaceuticals Ltd (CU6) is held across 13 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when CU6 moves, funds like IMPQ, ISO, SSO, VSO and OZXX that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 0.6% to CU6 , while the average exposure across all 13 ETFs that hold it is around 0.1% .

Top ETF holdings

eInvest Better Future (Managed Fund) (IMPQ) ~ 0.6%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0.2%
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) ~ 0.2%
Vanguard MSCI Australian Small Companies Index ETF (VSO) ~ 0.1%
Global X Australia ex Financials & Resources ETF (OZXX) ~ 0.1%

Last updated: ETF data and holdings as at 14 October 2026

Own CU6 directly or through an ETF?

How does holding Clarity Pharmaceuticals Ltd (CU6) shares directly compare to ETFs that include it?

	CU6 Direct	IMPQ ASX	ISO ASX	SSO ASX	VSO ASX	OZXX ASX
Holdings	1 company	42 holdings	218 holdings	219 holdings	203 holdings	105 holdings
CU6 Weight	100%	0.6%	0.2%	0.2%	0.1%	0.1%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	-	0.55% p.a.	0.5% p.a.	0.3% p.a.	0.25% p.a.
Approx. Yield	0%	-	4.57%	9.76%	4.93%	5.7%
Star Ratings	-	Not Rated

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CU6's direct yield. Annual cost uses each ETF's MER.

CU6 Exposure on $10,000 investment

How a $10,000 investment in Clarity Pharmaceuticals Ltd (CU6) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Clarity Pharmaceuticals Ltd (CU6)	Direct share	$1.825	-6.41%	-$641	$9,359
eInvest Better Future (Managed Fund) (IMPQ)	-	$3.980	0%	$0	$10,000
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$4.780	-3.04%	-$304	$9,696
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	Equity - Australia Small/Mid Cap	$13.750	-3.64%	-$364	$9,636
Vanguard MSCI Australian Small Companies Index ETF (VSO)	Equity - Australia Small/Mid Cap	$70.780	-1.99%	-$199	$9,801
Global X Australia ex Financials & Resources ETF (OZXX)	Equity - Australia Sectors	$9.880	0.41%	+$41	$10,041

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Clarity Pharmaceuticals Ltd (CU6) ETFs

13 ETFs hold Clarity Pharmaceuticals Ltd (CU6).

ETF	CU6 Weight	MER	Yield
eInvest Better Future (Managed Fund) (IMPQ)	0.6%	-	-
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0.2%	0.55%	4.57%
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	0.2%	0.5%	9.76%
Vanguard MSCI Australian Small Companies Index ETF (VSO)	0.1%	0.3%	4.93%
Global X Australia ex Financials & Resources ETF (OZXX)	0.1%	0.25%	5.7%
Plato Global Alpha Fund Complex ETF (PGA1)	0%	0.85%	-
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0%	0.16%	2.93%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	3.2%
Global X Australia 300 ETF (A300)	0%	0.03%	3.08%

View all 13 ETFs

Clarity Pharmaceuticals Ltd (CU6) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Clarity Pharmaceuticals Ltd (CU6) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clarity Pharmaceuticals Ltd (CU6) price-sensitive announcements

CU6 - SECuRE update

Clarity Pharmaceuticals Ltd (ASX: CU6) announced that the recruitment target for the Main

Clarity Pharmaceuticals Ltd (CU6)
8 Oct 2026 | 10:00 AM

CU6 - Bioshares Biotech Summit Presentation

Clarity Pharmaceuticals Ltd presented at the Bioshares Biotech Summit, highlighting their

Clarity Pharmaceuticals Ltd (CU6)
6 Aug 2026 | 9:57 AM

CU6 - SECuRE update

Clarity Pharmaceuticals Ltd has provided an update on its SECuRE trial, a Phase I/IIa stud

Clarity Pharmaceuticals Ltd (CU6)
5 Aug 2026 | 10:00 AM

CU6 - Quarterly Activities/Appendix 4C Cash Flow Report

Clarity Pharmaceuticals Ltd reported a cash balance of $178.3 million as of 30 June 2026,

Clarity Pharmaceuticals Ltd (CU6)
31 Jul 2026 | 12:08 PM

Clarity Pharmaceuticals Ltd (CU6) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	SAR-bisPSMA Presentation - Drug & Device Conference	13 Oct 2026 9:30AM	$1.920	$1.825	fallen by 4.95%
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	SECuRE update	8 Oct 2026 10:00AM	$1.910	$1.825	fallen by 4.45%
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	Becoming a substantial holder	5 Oct 2026 6:43PM	$2.090	$1.825	fallen by 12.68%
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	CORPORATE GOVERNANCE STATEMENT	30 Sep 2026 4:00PM	$2.100	$1.825	fallen by 13.10%
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	Appendix 4G	30 Sep 2026 3:52PM	$2.105	$1.825	fallen by 13.30%
Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID	Health Care	$681	Annual Report to shareholders	30 Sep 2026 3:45PM	$2.115	$1.825	fallen by 13.71%

CU6 Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$46.10	14.70%	0.00%	0.0%
2027F	C2	-$40.20	38.10%	0.00%	0.0%
2026A	-$107.14	-$29.10	44.50%	0.00%	0.0%

CU6 Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Clarity Pharmaceuticals Ltd (CU6)	$672M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,490M	-0.7857	0.2462	0.9655	84.4005	67.7241	34.4561	0.00%	1.68%	1.99%

CU6 Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	3.66	0.00
Market	0.31	13.80	1.05	0.71
Sector	0.76	43.30	2.75	2.07

CU6 Directors

Name	Position	Start Date
Dr Alan John Taylor	Executive Chairman, Executive Director	28 Nov 2013
Ms Michelle Parker	Executive Director	20 Sep 2024
Ms Rosanne Elizabeth Robinson	Lead Independent Director, Non-Executive Director	19 Oct 2010
Dr Christopher Graham Roberts	Non-Executive Director	24 Mar 2016
Ms Allison Rossiter	Non-Executive Director	16 Jul 2026

Clarity Pharmaceuticals Ltd (CU6) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 Apr 2026	PARKER, Michelle	Sell	Direct Shares	360,896	$3.056	$1,102,717.728
25 Nov 2025	PARKER, Michelle	Issued	Options	511,810	$1.616	$827,269.000
25 Nov 2025	BIGGIN, Colin	Issued	Options	487,439	$1.616	$787,875.000

See all changes in directors' interest & trades for Clarity Pharmaceuticals Ltd (CU6) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CU6 Management

Name	Position
Mr David Green	Chief Financial Officer
Robert Cochrane Vickery	Chief Financial Officer,Company Secretary

CU6 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clarity Pharmaceuticals Ltd (CU6). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
24,366,695 (6.55%)	HSBC Custody Nominees Pty Ltd
22,096,014 (5.94%)	Citicorp Nominees Pty Limited
20,704,111 (5.57%)	J P Morgan Nominees Australia Pty Limited

CU6 Calendar of Events

Date	Event
29 September 2027	Report (Annual)
26 August 2027	Report (Prelim)
26 February 2027	Report (Interim)
25 November 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us